David E Moller Selected Research

LY2405319

9/2013	The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
1/2013	Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David E Moller Research Topics

Disease

21	Type 2 Diabetes Mellitus (MODY) 11/2021 - 03/2002
12	Insulin Resistance 01/2022 - 03/2002
10	Obesity 06/2014 - 04/2003
7	Hyperglycemia 09/2006 - 03/2003
6	Dyslipidemias (Dyslipidemia) 01/2022 - 01/2002
6	Body Weight (Weight, Body) 09/2013 - 11/2004
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 04/2003
4	Inflammation (Inflammations) 01/2022 - 01/2002
3	Non-alcoholic Fatty Liver Disease 01/2022 - 11/2021
3	Hypertriglyceridemia 01/2005 - 03/2003
3	Atherosclerosis 03/2003 - 01/2002
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 01/2021
2	Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked) 01/2022 - 01/2022
2	Demyelinating Diseases (Demyelinating Disease) 01/2022 - 01/2002
2	Fatty Liver 12/2021 - 12/2008
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2013 - 06/2007
2	Cardiomegaly (Heart Hypertrophy) 09/2006 - 10/2003
2	Hypertrophy 11/2004 - 05/2003
1	Hyperlactatemia 01/2022
1	Lactic Acidosis 01/2022
1	Rare Diseases (Rare Disease) 01/2022
1	Renal Insufficiency (Renal Failure) 01/2022
1	Overweight 12/2021
1	Alcoholic Fatty Liver 11/2021
1	Hypoglycemia (Reactive Hypoglycemia) 07/2016
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2013
1	Metabolic Diseases (Metabolic Disease) 01/2012
1	Edema (Dropsy) 07/2009
1	Heart Failure 07/2009
1	Weight Gain 07/2009
1	Thrombosis (Thrombus) 06/2007
1	Glucose Intolerance 01/2005
1	Hypertension (High Blood Pressure) 01/2005
1	Hyperinsulinism (Hyperinsulinemia) 05/2004
1	Vascular Diseases (Vascular Disease) 04/2003

Drug/Important Bio-Agent (IBA)

8	PPAR gammaIBA 07/2009 - 03/2002
7	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2003
5	Triglycerides (Triacylglycerol)IBA 09/2013 - 03/2003
5	Insulin (Novolin)FDA Link 09/2013 - 03/2002
4	imegliminIBA 01/2022 - 01/2021
4	2- chloro- 3- (1- hydroxy- 5,6,7,8- tetrahydronaphthalen- 2- yl)- 6- oxo- 5- phenyl- 7H- thieno)(2,3- b)pyridin- 4- olate potassiumIBA 01/2022 - 11/2021
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 02/2006
4	fibroblast growth factor 21IBA 09/2013 - 12/2008
4	PPAR alphaIBA 09/2006 - 10/2003
4	LipidsIBA 04/2005 - 03/2003
3	Adenylate KinaseIBA 01/2022 - 11/2021
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2005
3	adomeglivantIBA 01/2017 - 07/2016
3	Glucagon Receptors (Glucagon Receptor)IBA 01/2017 - 07/2016
3	Nonesterified Fatty Acids (NEFA)IBA 06/2006 - 11/2004
3	Streptozocin (Streptozotocin)FDA Link 06/2006 - 03/2002
3	Rosiglitazone (Avandia)FDA Link 08/2003 - 03/2003
2	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 07/2002
2	Glucagon (Glukagon)FDA Link 07/2016 - 10/2013
2	LY2405319IBA 09/2013 - 01/2013
2	HDL CholesterolIBA 09/2013 - 01/2005
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 09/2006 - 01/2002
2	PPAR-gamma AgonistsIBA 09/2006 - 11/2004
2	CholesterolIBA 08/2005 - 07/2002
2	2,4-thiazolidinedione (thiazolidinedione)IBA 11/2004 - 04/2003
2	ThiazolidinedionesIBA 08/2002 - 01/2002
1	Member 1 Subfamily D ATP Binding Cassette TransporterIBA 01/2022
1	BiguanidesIBA 01/2022
1	DeuteriumIBA 01/2022
1	Gentamicins (Gentamicin)FDA LinkGeneric 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	ElementsIBA 01/2021
1	IncretinsIBA 10/2013
1	ApolipoproteinsIBA 09/2013
1	LDL CholesterolIBA 09/2013
1	AdiponectinIBA 09/2013
1	antineoplaston A10 (A 10)IBA 01/2013
1	Butyric Acid (Butanoic Acid)IBA 07/2009
1	Plasminogen Activators (Plasminogen Activator)IBA 06/2007
1	Glycoproteins (Glycoprotein)IBA 06/2007
1	CytokinesIBA 06/2007
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 06/2007
1	Dipeptidyl-Peptidase IV InhibitorsIBA 06/2006
1	Sitagliptin Phosphate (Januvia)FDA Link 06/2006
1	Fenofibrate (CiL)FDA LinkGeneric 08/2005
1	AcidsIBA 04/2005
1	LeptinIBA 11/2004
1	Hypoglycemic Agents (Hypoglycemics)IBA 06/2004
1	MK0767IBA 05/2004
1	Pioglitazone (Actos)FDA Link 05/2004
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 05/2003
1	Glucagon-Like Peptide 1 (GLP 1)IBA 05/2003
1	Lipoproteins (Lipoprotein)IBA 03/2003
1	Salicylic Acid (2 Hydroxybenzoic Acid)FDA LinkGeneric 01/2003
1	Protein Isoforms (Isoforms)IBA 01/2003
1	Serine (L-Serine)FDA Link 01/2003
1	phorbolIBA 01/2003
1	SalicylatesIBA 01/2003
1	Protein Kinase CIBA 01/2003
1	Insulin Receptor Substrate ProteinsIBA 01/2003
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2003
1	AMP-Activated Protein KinasesIBA 07/2002

Therapy/Procedure

8	Therapeutics 01/2022 - 04/2003
1	Glycemic Control 06/2006